Rhizome AI is an agent platform for life sciences that helps regulatory affairs teams understand FDA guidance through AI-powered research. The platform reads up to 1,000 documents per query and provides citations for all statements. It aims to reduce the large volume of office work required to bring a drug to market.
Rhizome AI
ActiveAgent Platform for Life Sciences
Total raised
$500K
1 round
Stage
Seed
Jan 2026
Team
1-10
since 2026
Pricing
—
Founded
2026
New York, United States
Agent-ready
—
AI agent platform built for life sciences
Research over FDA regulatory guidance documents
Ability to read up to 1,000 documents per query
Citations provided for every statement
Support for regulatory affairs workflows
Reduction of manual document review effort
Grounded answers tied to source documents
Focus on drug development and regulatory submissions
12/100
Early
MCP server
Public API
Webhooks
OAuth 2.0
SDKs
No public agent surfaces detected yet.
Jan 2026 Seed $500K ● Y Combinator
Capital network
$500K raised ·1 backer·10 network links
- Backers1
- Shared portfoliocompanies these backers also fund
- Extended networkfunds that co-invest alongside them
Resolve AI
AI SRE for complex production environments
AI AgentsAI Developer Tools
deepset
Haystack framework and deepset Cloud for enterprise LLM apps
AI AgentsAI Developer Tools
Wordware
Build AI agents by writing in plain English
AI AgentsAI Productivity
Wonderful
Multilingual enterprise AI agents for customer service
AI AgentsAI Productivity
Cursor
The AI code editor built for productive engineers.
AI CodingAI Agents
Oasis Security
Agentic access management to secure AI agents and non-human identities
AI AgentsAI for Cyber Defense
- How many documents can Rhizome AI read per query?
- The platform can read up to 1,000 documents per query and cites every statement it produces.
- Who is Rhizome AI built for?
- It is an agent platform for life sciences, designed to help regulatory affairs teams understand FDA guidance.
- Does it provide sources?
- Yes. It provides citations for all statements, helping regulatory teams verify answers against source documents.
- What problem does it address?
- It aims to reduce the large volume of office work required to interpret guidance and bring a drug to market.
Discussion
Sign in to join the discussion.
Sign inExplore more around Rhizome AI
Contextual paths to related AI startups, deals and rankings.